

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549**

FORM 8-K

**CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934**

Date of report (Date of earliest event reported): October 28, 2020 (October 22, 2020)

Acadia Healthcare Company, Inc.

(Exact Name of Registrant as Specified in Its Charter)

Delaware
(State or Other Jurisdiction
of Incorporation)

001-35331
(Commission
File Number)

45-2492228
(IRS Employer
Identification No.)

6100 Tower Circle, Suite 1000
Franklin, Tennessee
(Address of Principal Executive Offices)

37067
(Zip Code)

(615) 861-6000
(Registrant's Telephone Number, including Area Code)

Not Applicable
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (See General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol	Name of each exchange on which registered
Common Stock, \$0.01 par value	ACHC	NASDAQ Global Select Market

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers.

Effective October 22, 2020, the Board of Directors (the “Board”) of Acadia Healthcare Company, Inc. (the “Company”) increased the number of Class III directors serving on the Board from two to three and elected Michael J. Fucci to fill the vacancy created by the increase in the number of Class III directors. The term of office of Class III directors expires at the Company’s annual meeting of stockholders in 2023. The Board has not named Mr. Fucci to any committees of the Board.

Prior to his retirement in September 2020, Mr. Fucci served as Chairman Emeritus of Deloitte U.S. He previously served as Executive Chairman of Deloitte U.S. from 2015 to 2019, Chief Operating Officer of Deloitte Consulting from 2009 to 2015 and held various management positions since 2003.

Mr. Fucci will receive compensation for his service to the Company in accordance with the Company’s existing compensation plan for non-employee directors. Information with respect to the director compensation plan is set forth in the definitive proxy statement for the Company’s 2020 annual meeting of stockholders, filed with the Securities and Exchange Commission on March 25, 2020.

A copy of the press release announcing Mr. Fucci’s election to the Board is filed as [Exhibit 99](#) to this report.

Item 9.01. Financial Statements and Exhibits.

(d) [Exhibits](#)

<u>Exhibit No.</u>	<u>Description</u>
99	Press Release of Acadia Healthcare Company, Inc., dated October 28, 2020
104	Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ACADIA HEALTHCARE COMPANY, INC.

Date: October 28, 2020

By: /s/ Christopher L. Howard

Christopher L. Howard

Executive Vice President, Secretary and General Counsel

**Contact:**

Gretchen Hommrich
Director, Investor Relations
(615) 861-6000

**ACADIA HEALTHCARE NAMES FORMER DELOITTE U.S. CHAIRMAN
MICHAEL J. FUCCI TO BOARD OF DIRECTORS*****Adds Risk Management and Human Resource Expertise to Acadia Board***

FRANKLIN, Tenn. (October 28, 2020) — Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that Michael J. Fucci has been appointed to serve as an independent director on its Board of Directors. Mr. Fucci’s appointment, which is effective immediately, will increase the size of the Acadia Board to nine members, eight of whom are independent.

Prior to his retirement in September 2020, Mr. Fucci served as Chairman Emeritus of Deloitte U.S. He previously served as Executive Chairman of Deloitte U.S. from 2015 to 2019, Chief Operating Officer of Deloitte Consulting from 2009 to 2015 and held various management positions since 2003. He provided governance and operational leadership for Deloitte U.S. in critical areas such as organization strategy, leadership succession and risk mitigation, as well as executive performance and compensation. Mr. Fucci also served as a member on both the Deloitte U.S. and Deloitte Global Boards of Directors. While at Deloitte U.S., he established and co-chaired the Board Leadership Forum, a coalition of Fortune 500 board chairs and lead directors.

“We are pleased to welcome Mike Fucci to our Board of Directors as an independent director,” said Reeve B. Waud, Chairman of Acadia’s Board of Directors. “His impressive tenure of leadership experience as a principal and practitioner at Deloitte U.S. makes him an ideal Board member for Acadia. He brings a unique perspective on human resource transformation, corporate talent strategies and risk mitigation that will complement the work and expertise of our other directors. We look forward to his valuable contributions as we execute our growth strategy and pursue our primary objective to deliver long-term value for our stockholders.”

“I am honored to be joining the Acadia Board,” added Mr. Fucci. “I look forward to supporting Acadia’s important role as a leading behavioral healthcare provider, especially during a critical period of demand brought on by challenges associated with the COVID-19 global pandemic.”

About Acadia Healthcare Company, Inc.

Acadia is a leading provider of behavioral healthcare services. As of June 30, 2020, Acadia operated a network of 589 behavioral healthcare facilities with approximately 18,200 beds in 40 states, the United Kingdom and Puerto Rico. Acadia provides behavioral healthcare services to its patients in a variety of settings, including inpatient psychiatric hospitals, specialty treatment facilities, residential treatment centers and outpatient clinics.

-END-